NEWS: MEDITE Cancer Diagnostics, Inc., (OTC:MDIT / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining machines with a the total retail value of approximately $600,000. This is the first major sale to Mexico for MEDITE.
Also, MEDITE announces the first delivery of 10 units of MEDITE’s recently developed manual microtome M380 to the Chinese market through MEDITE’s distributor, UNIC Medical.
MEDITE’s Mexican distributor, ATYDE has ordered 13 units of MEDITE’s Programmable Slide Stainer TST44 and 18 units of MEDITE Continuous Linear Stainer COT20. “MEDITE’s tissue stainers are completely manufactured in Germany and provide a high level of automation, high quality and high throughput in staining human tissue for cancer diagnostics in histology laboratories. We look to expand our business with MEDITE since they are an experienced supplier which can address our needs for high quality, reliable and cost effective histology and cytology products,” stated Ms. Silvia Ramirez, Account Manager for ATYDE.
MEDITE also has delivered the first 10 units of the new manual microtome M380 to MEDITE’s Chinese partner UNIC Medical.
“We are excited about receiving the recently developed manual microtones from MEDITE. We expect this instrument to address the histology market needs at many Chinese medical institutions processing tissue samples for cancer diagnostics on a daily basis. MEDITE’s products which incorporate German standards of high quality engineered mechanics will enhance the quality of patient care and improve operating efficiencies at our client’s medical institutions. We believe this product will attract many buyers as it offers superior mechanical quality at an affordable price,” stated Ben Zheng, President of UNIC Medical.
“We believe MEDITE, the only German company manufacturing histology products in Germany such as the microtome M380, has set a superior standard worldwide incorporating the ability to cut human tissue sections thinner than 1 micron. The newly developed microtome M380 along with many of our current and future products address a burgeoning need in China, India and other rapidly growing countries by providing state of the art health care diagnostics tools for governments and private institutions allowing for the improvement of their citizens’ quality of life,” stated Michaela Ott, CEO of MEDITE Cancer Diagnostics, Inc.
As part of a government initiative, MEDITE along with its distribution partner UNIC Medical is working to standardize the Chinese histology laboratory process using MEDITE equipment, consumables, immuno-assays, along with the approved UNIC scanning technology for digitalization and computer aided diagnostics utilizing the latest cloud technology. UNIC Medical is a subsidiary of UNIC Group, a high tech company focused on automated digital optical quality assurance technology. In 2014, MEDITE successfully received Chinese Food and Drug Administration (“CFDA”) approval for all MEDITE histology laboratory devices. The CFDA application for the cytology product line currently is in preparation, and approval is expected in 2015.
About MEDITE Cancer Diagnostics, Inc.:
MEDITE Cancer Diagnostics Inc., is a Delaware registered company consisting of wholly-own MEDITE GmbH a Germany-based Company, with its subsidiaries CytoGlobe GmbH (Cytology Products, Germany), MEDITE GmbH (Distributor, Austria), MEDITE Inc. (Distributor, Americas) and MEDITE sp. z o.o. (R&D Poland). Since 1978, the MEDITE(R) group of companies has specialized in the development, manufacture and distribution of medical laboratory automation equipment and supplies for pathology, histology and cytology. For these fields, MEDITE offers a complete range of devices and consumables. MEDITE currently sells into 70 countries and is the market leader in Germany. Through CytoGlobe, a wholly owned subsidiary, MEDITE offers a full range of products for Cytology labs. Additional information on MEDITE’s products and services can be found at http://www.medite-group.com/.
On April 3, 2014, MEDITE was acquired by CytoCore, Inc. a bio molecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. The name of the company changed from CytoCore, Inc. to MEDITE Cancer Diagnostics, Inc. in December 2014.
This version of news story is Copr. © 2015 eNewsChannels™ (www.enewschannels.com) and the Neotrope® News Network – all commercial and reprint rights reserved. Unauthorized reproduction in whole or in part without express permission is prohibited.
